FTC Flags More Drug Patents for Improper Orange Book Listings
- May 03, 2024
The Federal Trade Commission (FTC) is disputing more than 300 patents for drug products such as those used to treat diabetes, asthma, and weight loss, including Novo Nordisk Inc.’s Ozempic, as improperly listed in the Food and Drug Administration’s (FDA’s) Orange Book.
ARTICLE TAGS
You must be logged in to access this content.